Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Technology May Prove Critical in New Cancer Drug Development
Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer Tremendous unmet need for patient-derived tumors (PDx) for new drug development - current mouse models unreliable TumorGenesis unique in the industry; its ovarian-cancer cells haven’t been widely available like most other PDx samples Multi-billion-dollar market opportunity As the precision-medicine industry continues to integrate technology to improve the efficiency and efficacy of its strategies, clinicians are realizing the need for actual patient samples to determine the best methods to defeat cancer. Researchers are now turning to patient-derived tumors (PDx) to better understand the complexities and vagaries…